Subconjunctival Hemorrhage as a Sign of Intraocular Retinoblastoma Progression to Orbital Retinoblastoma
Downloads
Introduction: Retinoblastoma is the most common intraocular malignancy of childhood. While treatable when detected early, a delayed diagnosis can lead to orbital extension, which significantly worsens the prognosis. We report an unusual case in which a subconjunctival hemorrhage signaled the progression of intraocular retinoblastoma to orbital involvement. Case Presentation: A 2-year-4-month-old child presented with a one-month history of left-eye leukocoria. Ocular ultrasound and computed tomography (CT) confirmed features of an intraocular retinoblastoma (Group E), and urgent enucleation was planned. The surgery was delayed by two months; shortly before the operation, the child developed an inferonasal subconjunctival hemorrhage that rapidly expanded. During enucleation, a reddish-brown extrascleral tumor was discovered beneath the hemorrhage, indicating orbital extension. Histopathology revealed Grade 3 retinoblastoma with optic nerve invasion (resection margin free of tumor). Adjuvant chemotherapy was initiated postoperatively. Conclusion: Subconjunctival hemorrhage can be an unusual warning sign of orbital tumor extension in retinoblastoma. This case highlights the importance of raising awareness and reducing diagnostic delays, particularly in resource-constrained settings.
Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, Ademola-Popoola DS, et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol 2020;6:685. https://doi.org/10.1001/jamaoncol.2019.6716.
Chawla B, Hada M. Orbital Retinoblastoma: Diagnosis and Management. Clinical Ophthalmic Oncology, Cham: Springer International Publishing; 2019.
Elam AR, Tseng VL, Rodriguez TM, Mike E V., Warren AK, Coleman AL, et al. Disparities in vision health and eye care. Ophthalmology 2022;129:e89–113. https://doi.org/10.1016/j.ophtha.2022.07.010.
Honavar S, Manjandavida F, Reddy VA. Orbital retinoblastoma: An update. Indian J Ophthalmol 2017;65:435. https://doi.org/10.4103/ijo.IJO_352_15.
Menon BS, Reddy SC, Maziah WM, Ham A, Rosline H. Extraocular retinoblastoma. Med Pediatr Oncol 2000;35:75–76. https://doi.org/10.1002/1096-911x(200007)35:1<75::aid-mpo13>3.0.co;2-2.
Abramson DH. Retinoblastoma: Saving life with vision. Annu Rev Med 2014;65:171–184. https://doi.org/10.1146/annurev-med-061312-123455.
Brar V, Couser N, Dhalla M, Goldman D, Kang K, Richards N, et al., editors. Fundamentals and Principles of Ophthalmology. 2023-2024 BCSC Basic and Clinical Science Course, San Francisco: American Academy of Ophthalmology; 2023.
Pedoman Nasional Pelayanan Kedokteran - Tata Laksana Retinoblastoma. Kementerian Kesehatan Republik Indonesia 2022. https://kemkes.go.id/eng/pnpk-2022---tata-laksana-retinoblastoma (accessed January 21, 2025).
Francis JH, Abramson DH, editors. Recent Advances in Retinoblastoma Treatment. Cham: Springer International Publishing; 2015.
Doz F, Khelfaoui F, Mosseri V, Validire P, Quintana E, Michon J, et al. The role of chemotherapy in orbital involvement of retinoblastoma. The experience of a single institution with 33 patients. Cancer 1994;74:722–732. https://doi.org/10.1002/1097-0142(19940715)74:2<722::AID-CNCR2820740228>3.0.CO;2-H.
Antoneli CBG, Steinhorst F, de Cássia Braga Ribeiro K, Novaes PERS, Chojniak MMM, Arias V, et al. Extraocular retinoblastoma: A 13-year experience. Cancer 2003;98:1292–1298. https://doi.org/10.1002/cncr.11647.
Goble RR, McKenzie J, Kingston JE, Plowman PN, Hungerford JL. Orbital recurrence of retinoblastoma successfully treated by combined therapy. Br J Ophthalmol 1990;74:97–98. https://doi.org/10.1136/bjo.74.2.97.
Dimaras H. Social Aspects, Advocacy and Organizations. Clinical Ophthalmic Oncology, Cham: Springer International Publishing; 2019.
Hungerford J, Kingston J, Plowman N. Orbital recurrence of retinoblastoma. Ophthalmic Paediatr Genet 1987;8:63–68. https://doi.org/10.3109/13816818709028518.
Marr B, Singh AD. Retinoblastoma: Evaluation and Diagnosis. Clinical Ophthalmic Oncology, Cham: Springer Nature Switzerland; 2024.
Copyright (c) 2025 Anas Jatikusuma, Delfitri Lutfi, Andi Cahyadi, Heriyawati

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Vision Science and Eye Health Journal by Universitas Airlangga is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The journal allows the author to hold the copyright of the article without restrictions. 
- The journal allows the author(s) to retain publishing rights without restrictions. 
- The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Share-Alike (CC BY-SA). 
- The Creative Commons Attribution-Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violations. 
 
						














